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Case presentations
Patient]. A 66-year-old man was first evaluated in the Renal Clinic of
the New England Medical Center (NEMC) at age 53. At age 9, he
developed periorbital and peripheral edema, gross hematuria, cylin-
druria, and proteinuria. He was told he had acute glomerulonephritis
and was confined to bed for one month; the edema and hematuria
resolved. He remained asymptomatic for the next four decades al-
though urinalyses performed during Army and insurance examinations
consistently revealed trace to I + protein.
At the age of 53, he noted intermittent pedal edema over a 3-month
period. Physical examination revealed a blood pressure 130/90 mm Hg.
The ocular fundi were normal. Cardiovascular examination was unre-
markable. No abdominal organomegaly was present. There was 1 +
pittingedema of the feet. Urinalysis revealed a specific gravity of 1.012,
a pH of 5, no sugar, 1 + protein, 3 to 5 red blood cells per high-power
field, no white blood cells, and rare granular casts. Twenty-four hour
urine protein excretion measured on three occasions ranged between
400 and 900 mg; no significant postural component to the protein
excretion was evident. Urine culture was sterile. The serum albumin
was 4.5 ing/dI. The serum creatinine was 1.1 mg/dl and the BUN was 17
mg/dl. The patient was believed to have 'latent glomerulonephritis' for
which no specific therapy was recommended. His edema resolved
spontaneously during the next several weeks.
During the ensuing 13 years, serial measurements of serum creatinine
revealed a slowly progressive decline in renal function (Table I). During
this period, urinalyses continued to reveal 1+ to 3+ protein and
occasional red blood cells. The patient developed mild hypertension,
treated initially with alpha-methyldopa, and later with propranolol. The
latter drug was discontinued 2 years ago because of mild hyperkalemia
(serum potassium 5.8 mEq/liter); however, the serum potassium con-
centration remained in the range of 5.0 to 5.4 mEq/liter subsequently.
Because of recent increasing fatigue, intermittent nausea, and pruritus,
plans are being made to initiate chronic hemodialysis.
Patient 2. A 44-year-old woman was first admitted to NEMC 12 years
ago because of acute renal failure. Three weeks earlier she had
complained of a mild sore throat lasting only a few days. One week
before admission she noted fever, palpitation, and painful erythematous
lesions and swelling over the anterior lower legs. Physical examination
at another hospital disclosed mild pharyngitis, erythema nodosum, and
tachycardia. Blood pressure was 134/82 mm Hg. Neither a heart
murmur nor edema was noted. An electrocardiogram revealed nonspe-
cific T-wave abnormalities, and p-hemolytic streptococcus was recov-
ered from a throat culture. The BUN was 12 mg/dl, and a urinalysis
revealed no protein and 2 to 3 red blood cells per high-power field.
Acute rheumatic fever was diagnosed, and treatment with erythromycin
and aspirin was begun. Fever, tachycardia, and cardiac abnormalities
improved, but edema developed. After 5 days, the urine output
suddenly ceased. The BUN rose swiftly to 117 mg/dl and the serum
creatinine increased to 4.7 mg/dl. The patient was transferred to NEMC
for further evaluation and treatment.
Her first pregnancy had been complicated by hypertension and
postpartum hemorrhage 10 years earlier. She denied a history of renal
disease, hypertension, diabetes, urinary tract infection, renal calculi, or
hematuria. She was allergic to penicillin.
Physical examination revealed a blood pressure of 120/70 mm Hg;
mild periorbital, sacral, and ankle edema; and erythema nodosum.
Urinalysis demonstrated 3+ protein, many red blood cells, and 3 to 4
red blood cell casts. Serum complement (C3) was subnormal; ANA and
LE preps were negative. Nephrotomography demonstrated 15.5 cm
kidneys. She was treated with peritoneal dialysis, oral Kayexalate,5
and a Giovanetti diet. An open renal biopsy 2 days later revealed
diffuse, exudative, and proliferative glomerulonephritis typical of acute
poststreptococcal glomerulonephritis. During the next 3 weeks, the
patient remained anuric and required 2 peritoneal dialyses. Despite
normal blood pressure (110 to 140/70 to 90 mm Hg), papilledema
occurred. The neurologic examination was otherwise normal.
One month after her illness began, urinary volume progressively
increased and she noted less fatigue. Renal function improved and
peritoneal dialysis was discontinued. Blood pressure rose to 150/115
mm Hg and therapy with alpha-methyldopa was begun. After another
month, the BUN had fallen to 11 mg/dl and the serum creatinine to 1.1
mg/dl. During the next 2 months she continued to feel well, and her
renal function remained normal. Hypertension persisted; the urinary
sediment contained 50 to 75 red blood cells per high-power field and
occasional red blood cell and granular casts. Urinary protein excretion
declined from 4.7 to 2.3 g daily. A second renal biopsy revealed one-
third of the glomeruli to be hyalinized, with more than one-half normal
or only slightly sclerotic. No cellular proliferation or exudation re-
mained. Hyaline droplet degeneration of proximal tubular cells and
protein casts within tubules were evident. The biopsy was interpreted
as revealing chronic, inactive proliferative glomerulonephritis.
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Table 1. Clinical course of patient 1
Age
Blood
pressure
mm Hg
Serum
creatinine
mg/dl
24-Hour urine
protein
grams
53 120/85 1.4 3.0
54 140/90 1.5
55 115/80 1.5 1.4
56 138/90 1.7 0.75
57 130/95 1.9
59 172/92 2.0 6.1
60 150/96 2.3 0.4
61 160/102 2.4 1.77
62 140/85 2.7 2.29
63 160/90 3.4
64 170/100 3.8
64.5 150/90 4.3 0.44
65 160/100 6.0
66 160/100 7.2 0.49
During the next 6 months, the serum creatinine remained unchanged
and hematuria disappeared. Retinopathy and hypertension resolved,
and antihypertensive therapy was withdrawn. Urinary protein excre-
tion fell to I g daily.
Nine years ago, hypertension reappeared (the blood pressure was
150/115 mm Hg), and treatment with alpha-methyldopa was reinstitut-
ed. A symptomatic proteus urinary tract infection 7 years ago was
treated with sulfonamides. An intravenous pyelogram was normal
(kidneys were 14.2 cm), the serum creatinine was 0.8 mg/dl, and
proteinuria was unchanged. Since then, urinary protein excretion has
gradually declined to 200 mg daily. Alpha-methyldopa was discontinued
because of fatigue. She takes 50 mg of hydrochlorothiazide daily and 40
mg of propranolol 4 times daily, and her blood pressure remains
relatively well controlled. Six months ago, physical examination was
normal. The BUN was 12 mg/dl and the serum creatinine was 0.9 mg/dI.
Urinalysis revealed I + proteinuria; no cells or casts were found in the
urinary sediment.
Discussion
DR. DAVID S. BALDWIN (Professor of Medicine, New York
University School of Medicine, New York, New York): The first
patient's story began when, at 9 years of age, he had an illness
labeled "acute glomerulonephritis." The early features of the
disease resolved in one month, but proteinuria persisted. He
developed hypertension 44 years later at age 53 years, and by
the time he was 66 years old—57 years after the apparent onset
of his renal disease—advanced renal failure necessitated the use
of hemodialysis. Is this clinical progression consistent with the
long-term course of acute glomerulonephritis, or should we
scrutinize the clinical features of this patient's disease to
determine whether another diagnosis would fit better?
The term acute glomerulonephritis implies the presence of a
disease characterized morphologically by diffuse endocapillary
proliferation in glomeruli, often with exudative features, and
occasionally with extracapillary proliferation as well. These are
the histologic features of immune complex-mediated, postinfec-
tious glomerulonephritis, of which poststreptococcal glomeru-
lonephritis (PSGN) is the prototype. Let us examine the course
of this patient's disease as compared with 185 patients with
sporadic (that is, nonepidemic) PSGN observed at Bellevue
Hospital, in whom a poststreptococcal cause was established in
all, and in whom the diagnosis was confirmed by renal biopsy in
two thirds [1]. Most of the patients in this series were adults; all
were hospitalized at onset.
We are given no information relative to the possible cause of
this patient's disease, so one cannot use failure to document an
antecedent group-A, 3-hemolytic streptococcus infection to
dismiss the diagnosis of PSGN. The early features that were
used to establish the clinical diagnosis of "acute nephritis"
included edema, gross hematuria, and proteinuria, Having no
further details, I will not dispute the likelihood that the clinical
features at least were compatible with acute glomerulonephri-
tis. What about the patient's subsequent clinical course? Per-
sistent proteinuria was observed in about one-half of our
patients with PSGN, but it has been described less often by
other observers, especially in series of children, and only rarely
in reports of epidemic PSGN. The recurrence of hypertension
many years after the onset of PSGN also is compatible with our
experience. The development of uremia was quite unusual in
our patients, although it did occur in a few. Persistent protein-
uria, moderate hypertension, and minimal impairment of renal
function were common. In our study, which began in 1960 and
includes new patients added throughout the subsequent 20
years, 10 of 185 patients now have advanced renal failure [2].
The only feature of this patient's clinical course that does not
appear compatible with postinfectious diffuse proliferative gb-
merulonephritis is the recurrence of edema many years after the
onset of the disease. In PSGN, edema typically occurs at onset,
may at times be associated with the nephrotic syndrome, and
subsides within days to weeks in association with remission of
the other initial manifestations in well over 90% of patients
studied. Edema may persist in the unusual patient in whom
severe, active renal disease continues and in whom progression
to irreversible renal failure occurs shortly after the onset of
PSGN or within one year or so. However, when the initial
features remit, as they typically do, neither edema nor the
nephrotic syndrome recurs except in those rare instances in
which the patient experiences a second episode of acute nephri-
tis. Of course, edema also can reappear in the terminal stage of
renal failure as a manifestation of the patient's marked function-
al impairment and limited ability to handle salt and water.
What other possibilities should we consider in the patient
whose early clinical features were compatible with acute ne-
phritis? Do any other glomerular diseases better explain this
patient's subsequent course than does postinfectious, diffuse,
proliferative glomerulonephritis? When this patient first be-
came ill, Berger's IgA nephropathy had not yet been described.
Yet one can easily understand how patients with gross hematu-
na, whom we now know might possibly have IgA nephropathy
or non-IgA focal glomerulonephritis, might have been thought
to have "acute gbomerubonephritis." The occurrence of edema
at onset, however, is rare (although not unheard of) in IgA
nephropathy. As our increasing experience with Berger's
nephropathy has taught us, the patient's slowly progressive
clinical course would be compatible with this diagnosis, but the
fact that the later development of edema and heavy proteinuria
was not associated with progression of renal failure over a
relatively short period of time virtually eliminates Berger's
nephropathy from the differential diagnosis. Another morpho-
logic entity that is occasionally marked by symptoms of "acute
nephritis" at onset is mesangiocapillary glomerulonephritis
(MCGN). We do not know the serum complement level, which
might be helpful in this differential diagnosis if persistent or
intermittent depression of C3 beyond the acute stage had
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occurred. In the course of MCGN, however, the nephrotic
syndrome is common, especially when the patient is becoming
uremic. I believe this patient's protracted clinical course and
particularly the absence of the nephrotic syndrome definitely
rule out the diagnosis of MCGN. Finally, extracapillary prolif-
erative (or crescentic) glomerulonephritis can have an acute
nephritic" onset, but the diagnosis is highly unlikely in this
patient; he was much too young, and his disease was too
indolent. Actually, the spectrum of crescentic glomerulonephri-
tis does include patients whose course is snot so rapidly
progressive," but a mild and brief acute episode followed by
slow progression over decades is not compatible with this
diagnosis.
Diffuse endocapillary proliferative glomerulonephritis, there-
fore, is probably the corrrect morphologic diagnosis. Slow
progression to glomerular sclerosis and end-stage renal failure
occurred even though the initial episode was mild and minimal
proteinuria was the only manifestation for more than 40 years.
We know from similar observations in patients with docu-
mented PSGN that, during the years following the acute stage,
proliferation is no longer present in glomeruli, and immunopath-
ologic evidence of immune-complex disease is no longer de-
monstrable. Yet the disease progresses. In a moment we will
consider possible nonimmunologic mechanisms by which gb-
merulonephritis might progress in such patients.
The second patient described today provides a fascinating
contrast with the first. In this woman, PSGN was documented
by bacteriologic, clinical, and morphologic criteria at age 44
years. Although her disease was severe enough to necessitate
dialysis during the initial 3 weeks, her course has been relative-
ly benign over the subsequent 12 years of followup. On the
other hand, our first patient, who seemed to have mild acute
nephritis, ultimately developed uremia. For more than 4 dec-
ades, however, he showed only minimal evidence of glomerular
disease, and his clinical course was very similar to the experi-
ence of our second patient during the 12 years since her initial
episode. In relating the severity of disease at onset in PSGN to
the eventual outcome, we have observed a correlation between
the severity of initial clinical and morphologic manifestations
and the presence of hypertension, proteinuria, renal functional
impairment, and glomerular sclerosis 2 or more years from
onset [1]. Patients who had mild disease initially were not
protected from developing chronic disease, however. It is even
more interesting that most of the patients who eventually
became uremic experienced periods of several years with only
minor manifestations of disease: little or no proteinuria, normal
blood pressure or mild hypertension, and creatinine clearance
in the normal range [2].
The classic episode of acute PSGN in the second patient
occurred in concert with acute rheumatic fever and erythema
nodosum following a documented group-A, -hemo1ytic strep-
tococcus pharyngitis. Not only was the infectious cause estab-
lished, but in addition a renal biopsy showed the typical findings
of diffuse endocapillary proliferative glomerubonephritis, and
serum complement was decreased. The patient, who became
anuric at the onset and remained so for 3 weeks, required
peritoneal dialysis. With PSGN of this severity, one would
expect the presence of extracapillary as well as endocapillary
proliferation, but this finding was not described.
Although most patients with acute PSGN who have oliguria
or anuria for more than a few days usually have extensive
extracapillary proliferation and often do not regain renal func-
tion, a diuresis occurred after 3 weeks and renal function
returned to normal during the next month. Because hyperten-
sion and heavy proteinuria persisted, another renal biopsy was
performed 4 months from onset; this time the biopsy revealed
remitted acute PSGN, now with sclerosis of one-third of
glomeruli but without proliferation. During the next 6 months,
hypertension and retinopathy subsided and the urinary protein
excretion diminished; renal function remained normal. Hyper-
tension reappeared 3 years after onset, and for the subsequent 9
years of follow-up, the patient's hypertension has been con-
trolled with medication, she has had minimal but persistent
proteinuria, and she has maintained normal renal function.
Despite the severity of the disease at onset, this patient's
course has been relatively benign thus far. The development of
glomerular sclerosis and the reappearance and persistence of
hypertension and proteinuria indicate, however, that irrevers-
ible damage accompanied the acute episode. The features of the
long-term course in this patient are typical of those we have
observed in the majority of our adult patients who have been
followed for 10 years or more [3]. In many, the evidence of
progressive disease is lacking, but hypertension and protein-
uria, both sequelae of the acute attack, persist. In others,
manifestations that remitted early have reappeared, and slow
progression has occurred. A few have advanced to end-stage
renal failure. In today's first patient, 44 years elapsed between
the onset of the disease and terminal uremia. The second
patient, whose disease began when she was in her 40s and who
has evidence of chronic disease 12 years later, can be expected
to have a slowly progressive course, but she probably never will
have clinically significant renal insufficiency.
The importance of these two case histories is not that they
merely teach us that PSGN can insidiously lead to uremia over
many years after the early features of the disease subside. After
all, PSGN is now an uncommon disease, as is acute rheumatic
fever, the other sequel of 3-hemolytic streptococcal infection.
But these observations on the continued progression of PSGN
after the initial immune process has subsided have provided the
stimulus for us to speculate on what factors, other than immune
mechanisms, might be capable of producing gbomerular dam-
age. It seems highly likely to me that if nonimmunobogic
mechanisms of glomerular injury are responsible for progres-
sion in PSGN, these mechanisms probably play a role in other
glomerular diseases as well. I'd now like to turn to a discussion
of these mechanisms.
An immunopathogenetic mechanism—immune complex or
antiglomerular basement membrane antibody—is held responsi-
ble for most forms of primary glomerular disease in humans.
Although immunologic mechanisms and the mediators of
glomerular damage that they induce might form the basis for
initiating most glomerular diseases, certain clinical observa-
tions and experimental data suggest that the progression of
these diseases is influenced by several nonimmunobogic factors.
Intrarenal vascular disease. Sclerosis of arterioles and prear-
terioles, a common finding in advanced glomerular disease, has
long been recognized at postmortem examination and conven-
tionally has been interpreted as an effect of hypertension.
Researchers thus have assumed that ischemic glomerular scle-
rosis resulting from intrarenal vascular disease contributes to
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Glomerular histology Vascular lesions
Minor glomerular lesions
Membranous nephropathy
Diffuse proliferative glomerulonephritis
Focal and segmental glomerulonephritis
44/68
20/37
91/123
96/1 16
64.7%
54.1%
74.0%
82.6%
a Data taken from Ref. 11.
the progression of renal failure during the hypertensive stage of
glomerular disease and, consequently, the importance of con-
trot of blood pressure has been stressed [4—8].
Matignant hypertension can occur with glomerulonephritis,
and the associated necrotizing arteriolitis of the renal vessels
might justifiably be attributed to the marked elevation of
diastotic blood pressure. The frequent occurrence of intrarenal
vascutar sclerosis early in the course of glomerulonephritis
prior to the advent of hypertension, or with only mild elevation
of blood pressure, however, suggests a particular susceptibility
of the renal arterioles to the effects of hypertension in glomeru-
lonephritis, or perhaps indicates that vascular disease even
might be a primary feature of the disease rather than a second-
ary manifestation of hypertension.
We have studied biopsies in patients in intermediate stages of
poststreptococcal glomerulonephritis [9], and in Berger's IgA
nephropathy [10], when renal function is normal or minimally
impaired and hypertension is mild or absent. The results
demonstrate a high incidence of arteriolar and prearteriolar
sclerosis. Similar observations have been made in a variety of
other glomerular diseases in which vascular sclerosis exceeded
the damage that one would anticipate for the age of the patient
and the duration and severity of hypertension. Kincaid-Smith
reported that the incidence of renal arterial and arteriolar
lesions ranged from 54% to 82% in normotensive patients under
age 40 years who had various forms of glomerulonephritis [11]
(Table 2).
In our studies, vascular changes closely correlated with
gtomerutar sclerosis and suggested to us a cause-and-effect
relationship in which ischemia was responsible for glomerular
damage. As shown in Figure 1, 21 renal biopsy specimens from
patients with poststreptococcal gtomerulonephritis were judged
to have a significantly greater frequency of gtomerular sclerosis
than did specimens from age-matched controls; 17 ofthe 21 also
showed arteriolar sclerosis. In 19 specimens unaffected by
glomerular sclerosis, only 5 showed arteriolar sclerosis. A
similar correlation was demonstrated for Berger's IgA nephrop-
athy. Sixteen of 20 specimens with significantly more glomeru-
lar sclerosis than expected showed arteriolar sclerosis as well;
of 26 specimens without glomerular sclerosis, only 4 had
arteriolar sclerosis.
The frequent presence of ischemic or "collapse-type" sclero-
sis of the glomeruli rather than disorganization of glomerular
structure seemed to lend further support to a causative role for
vascular sclerosis in the progression of these glomerular dis-
eases [9, 10]. Such an hypothesis is especially attractive for our
understanding of PSGN in which immune damage almost
certainly abates within one year or so from onset, as evidenced
by the usual absence of immunoglobulins in glomeruli beyond
0.1
Fig. 1. Correlation between glomerular sclerosis and vascular sclerosis
in poststreptococcal glomerulonephritis. Percentage of sclerotic gb-
meruli on renal biopsy is plotted against age of the patient. The mean
(shaded band) and the 95% population confidence limits are shown for
the regression of gbomerular sclerosis against age in normals [61].
Appropriate symbols indicate for each datum whether vascular scbero-
sis was absent, equivocal, or definitely present. The correlation be-
tween gbomerular sclerosis and vascular sclerosis is highly significant (P
< 0.002). Data from Ref. 9.
this time [12]. Under these circumstances, progressive gbomeru-
tar sclerosis requires the operation of nonimmunologic mecha-
nisms, and the clinical and pathologic evidence just cited
supports the theory that vascular disease and resultant ischemia
cause progressive renal damage. Recent hemodynamic and
morphologic observations in the remnant kidney and in experi-
mental nephritis suggest, however, that adaptive increases in
perfusion following nephron loss or injury can be responsible
for further glomerular damage. The emphasis thus has shifted
away from ischemic glomerular sclerosis to hyperperfusion as a
possible mechanism for both vascular and glomerular injury in
chronic glomerulonephritis.
Adaptive changes in glomerular hemodynamics. Studies in
experimental animals show that removal of about five-sixths of
renal mass results in proteinuria, hypertension, progressive
renal failure, and advanced glomerular sclerosis [13—151. This
finding suggests that adaptive alterations in renal hemodynam-
ics, or other factors related to reduced renal mass and its
biochemical consequences, can cause further renal damage.
Such mechanisms could contribute to ongoing parenchymal
destruction in patients with renal disease regardless of the initial
cause of reduced renal parenchymal mass.
Brenner and coworkers, in studies of glomerular hemody-
namics in the remnant kidney, have demonstrated adaptive
increments in glomerular blood flow and single-nephron GFR
[16—18] (Table 3). Despite only a minimal increase in systemic
arterial pressure, transcapillary hydraulic pressure significantly
increased as a result of elevated glomerular capillary hydraulic
pressure. Adaptive reductions in afferent arteriolar resistance
must account for the increased transmission of systemic pres-
Table 2. Arterial and arteriolar lesions in normotensive patients with
glomerulonephritis (age under 40 years)a
• No vascular sclerosis
£ Equivocal vascular sclerosis
* Definite vascular sclerosis
a)
Ca
a)
E0
0
C-)
0
30
20
10
5
£
0 50
Age (years)
60 70 80
Nonimmunologic mechanisms of glomerulonephritis 113
Table 3. Increased glomerular pressure and flow in remnant kidneysb
mm Hg
BUN
mgldl
GFR
mi/mm
SNGFR
ni/mm
QAd
nI/mm mm Hg
Remnant kidney 128 4 94 9 0.21 .03 62 6 187 20 44.2 2.2
Control kidney Ill 3 20 3 0.70 .07 27 4 75 12 36.6 1.7
a Data taken from Ref. 18.
b AP refers to systemic pressure.
SNGFR refers to single nephron GFR.
d refers to glomerular plasma flow.
P refers to transcapillary hydraulic pressure.
sure to the glomerular capillaries and for the increments in
glomerular perfusion. The authors suggest that these adaptive
changes might have an adverse effect on renal function by
accelerating glomerular sclerosis in the remaining glomeruli.
The alterations in glomerular hemodynamics that occur in the
remnant kidney resemble those that Azar et a! have described in
one-kidney, "post-salt" hypertension, in which glomerular
sclerosis was associated with reduced arteriolar resistance and
increases in transcapillary pressure, glomerular blood flow, and
single-nephron GFR [19].
Maddox et al have shown that Munich-Wistar rats with
recently induced, mild to moderate nephrotoxic serum nephritis
(NSN) maintain normal glomerular plasma flow rates and
single-nephron GFR despite morphologic evidence of wide-
spread glomerular injury [20]. Transcapillary hydraulic pressure
was considerably elevated due to increased glomerular capillary
pressure, and single-nephron GFR failed to increase only
because of a reduction in the ultrafiltration coefficient; the
authors attribute these results to the loss of patent capillaries in
NSN. Allison, Wilson, and Gottschalk found that these same
pressures remain elevated in rats with chronic glomerulonephri-
tis [21]. Thus, adaptive decreases in afferent arteriolar resist-
ance must occur in the course of glomerulonephritis as they do
in reduced renal mass, thereby exposing the glomeruli to
increased intracapillary pressures.
Further evidence of secondary glomerular damage in the
remnant kidney has been provided by Olson et al, who found
that endothelial and epithelial cell abnormalities occur along
with altered charge and size-selective properties of the glomeru-
lar wall [221. These authors showed a reduction in the charge-
selective barrier to filtration in the remnant kidney by demon-
strating that the fractional clearance of anionic horseradish
peroxidase was increased, whereas that of the cationic form
was decreased. Fractional clearance of low-molecular-weight
neutral dextrans was not affected, but the clearance of higher-
molecular-weight neutral dextrans was practically doubled;
these changes suggested impairment of glomerular size selec-
tively as well.
Utilizing cationic probe molecules, Shea, Raskova, and Mor-
rison showed that proteinuria in the subtotally nephrectomized
rat was not accompanied by changes in the ultrastructural
distribution of anionic sites in the glomerular basement mem-
brane [23]. These investigators have suggested, rather, that
proteinuria in the remnant kidney results from sustained rises in
glomerular capillary pressure that, in turn, cause an increase in
pore size.
Direct effect of hypertension on glomerular structure and
function. The occlusive effect of hypertension on the renal
arterioles and prearterioles is generally accepted as the mecha-
nism by which hypertension aggravates the course of glomeru-
lonephritis. Vascular narrowing is thought to accelerate glomer-
ular sclerosis through ischemia. The "vicious cycle in Bright's
disease" as proposed by Wilson and Byrom alludes to this
mechanism [24]. However, a number of recent studies in
experimental hypertension and in hypertension superimposed
on a variety of glomerular diseases provide evidence that
glomerular damage might be produced directly by hypertension
rather than secondarily through ischemia resulting from occlu-
sive small vessel alterations.
Knowlton et al, in 1946, administered DOCA to rats with
nephrotoxic serum nephritis and produced severe hypertension
and a worsening of the glomerular disease; the authors reported
no change in proteinuria [25]. In a series of studies in which
NSN was induced in animals with preexisting hypertension,
Masuyama and associates observed increased severity of hy-
pertension and more persistent proliferative and sclerotic
changes in glomeruli; vascular alterations were not described
[26—28]. Motoki et al produced hypertension with DOCA and
salt-loading in the unilaterally nephrectomized rat with NSN
and noted increased glomerular proliferation and sclerosis [29].
Teodoru, Saifer, and Frankel showed that more rabbits with
NSN develop severe glomerulonephritis and die of uremia if
they have been unilaterally nephrectomized or salt loaded
beforehand [30]. Blood pressure measurements were not per-
formed in this study, but one can presume that the salt-loaded
rabbits were hypertensive. Increased proteinuria and prolifera-
tive-sclerotic glomerular changes were reported by Tikkanen
and associates, who superimposed DOCA-salt hypertension on
autologous immune glomerulonephritis (Heymann nephritis) in
the rat; vascular sclerosis and necrosis occurred infrequently in
this model [31]. Using DOCA-salt hypertension in heterologous
immune glomerulonephritis (passive Heymann nephritis), Iver-
son and Ofstad noted more marked glomerular basement mem-
brane thickening, greater proteinuna, and a shortened life span
of the experimental animals [32].
In a study of steroid-induced hypertension in the uninephrec-
tomized rat, Hill and Heptinstall first suggested in 1968 that
failure of adequate arteriolar constriction rather than excessive
narrowing was responsible for the hypertensive lesions that
developed in insufficiently hypertrophied vessels and their
"unprotected" glomeruli [33]. The following year, Still and
Dennison demonstrated, in a study of DOCA-salt hypertension
in the uninephrectomized rat, that glomeruli could undergo cell
swelling and sclerosis that resembled changes in arterioles; they
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No./hr
Blood
pressure
mm Hg
Cardiac
indexa
%
Proteinuria
mg124 hr
Control 17 102 2 .27 .01 2 2
NSNb 12 105 2 .25 .01 24 12
CW 16 145 3 .36 .01 27 11
NSN + CH 15 142 6 .36 .03 144 28
suggested that hypertension might directly damage the glomeru-
lar capillary [34]. The vascular and glomerular damage de-
scribed by these authors probably was attributable to malignant
hypertension, but they introduced a new and important con-
cept—that glomerular vessels are affected directly by hyperten-
sion and do not suffer merely as a secondary result of arteriolar
narrowing and ischemia.
Azar et al, in studies of one-kidney, "post-salt" hypertension
in the rat, recently showed proliferation and sclerosis of glomer-
uli in association with reduced arteriolar resistance and in-
creases in transcapillary pressure, glomerular blood flow, and
single-nephron GFR [191. These investigators suggested that
adaptive decreases in afferent resistance following uninephrec-
tomy overrode the ability of arterioles to increase their resist-
ance in the presence of superimposed hypertension, thus expos-
ing the glomerular capillaries to damaging increases in hydraulic
pressure. In a subsequent study, these authors demonstrated
that salt-sensitive rats who develop hypertension with both
kidneys intact show similar increases in single-nephron GFR
that result from elevated glomerular blood flow and glomerular
transcapillary hydraulic pressure [35]. The authors propose that
the glomerular lesions in these rats are attributable to high
glomerular capillary pressures that occur when hypertension
and nephrosclerosis are superimposed on the genetically re-
duced number of adapted nephrons known to exist in this
strain.
In related studies, Mauer and associates examined the effect
of hypertension produced by renal artery clipping on streptozo-
tocin-induced diabetes mellitus in the rat. They observed in-
creased mesangial matrix material and heavier deposits of IgG,
1gM, and C3 in the unclipped "diabetic" kidney [36]. Addition-
al evidence for the possible role of glomerular hemodynamic
factors in diabetic glomerulosclerosis was adduced by Azar,
who demonstrated that glomerular capillary pressure is in-
creased prior to any morphologic changes in rats with short-
term diabetes induced by pancreatectomy [37]. Finally, Hostet-
ter et al recently reported glomerular hyperfiltration in moder-
ately hyperglycemic Munich-Wistar rats made diabetic with
streptozotocin [38]. This hyperfiltration resulted from eleva-
tions in glomerular plasma flow and increases in transcapillary
hydraulic pressure difference.
We have examined the effect of superimposed renal artery
clip hypertension (CH) on the clinical and morphologic features
of NSN in the Sprague-Dawley rat [39]. Our objective was to
determine (1) whether the effects on the renal arterioles of a
given elevation in blood pressure were increased in the nephrit-
ic animal; and (2) whether the glomerular abnormalities of NSN
Table 4. Effect of clip hypertension on nephrotoxic serum nephritis 100 Sacrifices 1 and 2 Sacrifices 3, 4 and 5
a Cardiac index refers to the heart weight to body weight ratio (%).
b NSN refers to nephrotoxic serum nephritis.
CH refers to clip hypertension.
100
—
100
Proliferation
and
tuft necrosis
Glomerular
sclerosis
— __________ —
Vascular
— sclerosis
n 16 8 19 10 17 12 16 15
C NSN CH NSN C NSN CH NSN
+CH +CH
Fig. 2. Incidence of glomerular and vascular morphologic lesions in
nephrotoxic serum nephritis, in clip hypertension, and in the combina-
(ion of nephrotoxic serum nephritis with clip hypertension. The super-
imposition of clip hypertension (CH) on nephrotoxic serum nephritis(NSN) increased the incidence of glomerular proliferation, tuft necro-
sis, and sclerosis, and resulted in the appearance of vascular sclerosis
(arteriolar medial hypertrophy) in almost every instance.
would be aggravated by concomitant hypertension. To avoid
the catastrophic effects of necrotizing vasculitis that would be
anticipated with marked elevations in blood pressure and which
could obscure differences between hypertension alone and
hypertension superimposed on NSN, we selected animals for
comparison that had mean systolic blood pressures ranging
between 120 and 160 mm Hg. Further, we attempted to induce a
mild form of NSN to facilitate the recognition of any magnified
effects of superimposed hypertension on the severity of glomer-
ular lesions.
Table 4 includes data for all animals sacrificed at 3, 4, and 5
months after application of the renal artery clip, which followed
injections of nephrotoxic serum by one month. Data for control
animals and those with NSN alone and CH alone are given for
comparison. The mean systolic blood pressures in the two
hypertensive groups were almost identical; the similarity in
heart weight to body weight ratios lends support to the close
correspondence in measured blood pressures in the CH and
NSN + CH groups. As Table 4 shows, the superimposition of
hypertension on NSN markedly increased the level of protein
excretion at the time of each monthly sacrifice. The incidence
and severity of glomerular and vascular lesions similarly were
aggravated by the superimposition of hypertension on NSN
(Figs. 2—5). Whereas the occurrence of glomerular proliferation
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Fig. 3. Nephrotoxic serum nephritis. Photomicrograph of rat kidney 3
months after administration of nephrotoxic serum. Blood pressure was
98 mm Hg. Glomeruli show increased mesangial matrix; a single
glomerulus is sclerotic. Several small arteries present in the field are
normal. Periodic acid-silver methenamine counterstained with hema-
toxylin and eosin. (x 180).
Fig. 4. Clip hypertension. Photomicrograph of unclipped right kidney 4
months after application of clip to left renal artery. Blood pressure was
149 mm Hg. Glomeruli show increased mesangial matrix; a single
glomerulus is sclerotic. A normal small artery is shown. Periodic acid-
silver methenamine counterstained with hematoxylin and eosin.
(x 180).
and tuft necrosis never exceeded approximately 20% in rats
with CH or NSN alone, when CH was combined with NSN, the
incidence of these glomerular abnormalities exceeded 80% in
the latter stages of the experiment. The incidence and severity
of glomerular sclerosis similarly increased in rats with CH
superimposed on NSN. Arteriolar medial hypertrophy was not
noted in rats with NSN and occurred mildly and only occasion-
ally in rats with CH; the incidence of severe arteriolar sclerosis
reached almost 100% when hypertension was combined with
NSN.
Our studies demonstrate that the superimposition of hyper-
tension in the rat with NSN markedly aggravates the glomerular
abnormalities and induces changes in the renal arterioles that do
not occur in NSN alone or in CH alone at comparable levels of
Fig. 5. Nephrotoxic serum nephritis with superimposed clip hyperten-
sion. Photomicrograph of unclipped right kidney 3 months after admin-
istration of nephrotoxic serum and 2 months after application of clip to
left renal artery. Blood pressure was 140 mm Hg. Glomeruli show
widespread sclerosis and severe intra- and extracapillary proliferation.
Medial hypertrophy and intimal hyaline are present in prearterioles;
there are no necrotizing vascular lesions. Periodic acid-silver methena-
mine counterstained with hematoxylin and eosin. (x 180).
systolic blood pressure. The results suggest that the intrarenal
vessels in experimental nephritis might be abnormal in a way
that renders them more susceptible to the effects of increased
intraluminal pressure, even though these vessels appear mor-
phologically unaffected by the disease, The diseased glomerular
capillaries might be showing a similar increased susceptibility to
damage. On the other hand, one could hypothesize that the
glomerulus in experimental nephritis actually is exposed to
greater hydraulic pressure and flow than might normally occur
at a given systemic pressure. Such increases could be due to
adaptive alterations in renal resistance that accompany glomer-
ular disease. The failure of arteriolar constriction to occur in the
presence of systemic hypertension could lead to hyperfiltration
and resultant acceleration of glomerular proliferation and scle-
rosis. This afferent arteriolar faiIure" also might be responsi-
ble for the markedly increased frequency and severity of small
vessel damage that occurs at a given level of systemic pressure
when hypertension is combined with glomerulonephritis.
Adverse role of dietary protein in experimental nephritis and
in a model of renal ablation. Numerous investigators have
explored a possible deleterious effect of dietary protein on the
course of experimental nephritis and on the progressive renal
failure that occurs with subtotal renal ablation. On balance, the
available evidence indicates that high protein intake accelerates
renal failure in both models. In 1939, Farr and Smadel showed
that in rats with NSN given a 5% protein intake, clinical renal
disease subsided rapidly and glomerular and tubular injury
resolved [40, 41]. By contrast, rats fed a diet containing 40%
protein uniformly developed renal failure and died within one
year. Postmortem examination revealed progressive scarring
and destruction of tubules and glomeruli. Rats fed a basal or
mixed-stock diet followed a course that was intermediate
between results from the extremes of protein intake.
Earlier, Medlar and Blatherwick [42, 43] and Kennedy in
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Table 5. Preservation of renal function in remnant kidney by phosphorus restrictionb
Time
Urea nitrogen Creatinine
Normal diet
mg/dl
phate restriction
mgldlNb
Normal diet
mg!dl
Phosph
N1'
ate restriction
mg/dl
Phos
Before nephrectomy
Day 28
Day 49
Day 70
Day 84
Day 105
Day 168
26
24
20
15
12
7
All dead
20 0.5
107 6
111 60
118 120
146 150
186 260
12
12
10
10
10
10
9
18 0.7
85 6
75 4
67 3
69 10
69 5
52 3
0.46 .02
1.43 0.08
1.46 0.090
1.87 0.160
2.87 0.35c
3.75 0.570
All dead
0.60 .04
1.26 0.07
1.12 0.05
1.13 0.05
1.11 0.05
1.0! 0.02
0.76 .03
Reprinted, by permission of the New England Journal of Medicine 298: 122—126, 1978 (Ref. 50).
b N refers to the number of animals alive at that time.
P < 0.01 for differences between animals on normal diet and phosphate-restricted animals at same time.
1957 [44] had suggested that sclerosis occurring with aging,
uninephrectomy, or both could be accelerated by high-protein
feeding. Lalich and Allen studied unilaterally nephrectomized
rats fed diets containing 30% protein and found excessive
proteinuria followed by ultrastructural changes leading to even-
tual sclerosis of glomeruli [45]. In a recent study, Kleinknecht
and associates examined the effects of various protein diets on
growth, renal function, and survival in Wistar rats who were
subjected to ablation of seven-eighths of their renal mass [46]. A
diet containing 37% protein led to anorexia, growth failure, and
rapid deterioration of renal function in these rats. Although the
content of sodium, phosphate, and calcium also was higher in
the high-protein diets, none of the dietary regimens was low in
these minerals, so an important, albeit not exclusive, deleteri-
ous role for protein was established in these studies.
The mechanism by which high protein intake accelerates
glomerular sclerosis in animals with experimental nephritis,
with subtotal renal ablation, or with aging has not been elucidat-
ed. However, studies by Shannon, Joliffe, and Smith [47], Van
Slyke et al [481, and Pitts [491 in the 1930s might be relevant to
this issue. These authors showed that urea clearance, filtration
rate, and renal blood flow could be increased two- to threefold
in the dog by high-protein feeding. Once again, a possible role
for increased glomerular perfusion and hyperfiltration in the
causation of sclerosis is suggested. There are as yet no adequate
clinical studies in humans that examine the relationship be-
tween protein intake and the course of parenchymal renal
disease.
Phosphorus restriction and preservation of renal function.
Preservation of renal function by phosphorus restriction has
been demonstrated in the renal ablation model by Ibels and
associates [50] and in nephrotoxic serum nephritis in the rat by
Karlinsky [51]. Ibels and colleagues reported prevention of
proteinuria, renal calcification, histologic changes, functional
deterioration, and death from uremia (Table 5). Similar salutary
effects were noted in the phosphorus-restricted rat with experi-
mental nephritis. The mechanism by which phosphorus restric-
tion prevents functional deterioration in the remnant or the
diseased kidney is not known [52]. One obvious possibility is
that dystrophic and metastatic renal calcification in the cauter-
ized remnant is prevented through suppression of secondary
hyperparathyroidism and a reduction in calcium-phosphorus
product. However, the striking protective effect of phosphorus
restriction on the glomerular lesions of nephrotoxic serum
nephritis suggests that mechanisms of renal damage other than
calcification alone must be involved.
Glomerular sclerosis and aging. The occurrence of protein-
uria in the aging male rat has long been recognized [53, 54].
Although this proteinuria rarely gives rise to the nephrotic
syndrome, renal lesions closely resembling focal and segmental
glomerular sclerosis in humans are common in several species
of aging male rats [45, 551. This phenomenon is of interest as a
possible model for the investigation of the mechanisms respon-
sible for progressive glomerular injury and sclerosis in human
renal diseases. Protein loading accelerates the development of
the lesion [42, 43, 45], whereas low sodium intake prevents both
the increasing proteinuria and glomerular sclerosis [56]. Unilat-
eral nephrectomy increases the incidence of glomerular sclero-
sis in the aging rat, especially when combined with increased
dietary protein intake [57]. Recent ultrastructural and immuno-
fluorescent observations have demonstrated increased 1gM
deposits in the mesangium as well as progressive glomerular
basement membrane and epithelial cell damage associated with
nonselective proteinuria [58—601.
These studies prompted the hypothesis that focal glomerular
sclerosis in the aging rat might result from mesangial overload
and dysfunction consequent to a persistent increase in glomeru-
lar permeability and proteinuria. By analogy, one can argue that
mesangial functional overload and its consequences play a
similar role in human glomerular diseases, especially when the
hemodynamic consequences of reduced renal mass and hyper-
tension are superimposed on damaged glomerular capillaries.
Age-related glomerular sclerosis also occurs as a phenome-
non of aging in humans. Kaplan et al, in a postmortem study,
found that the incidence of glomerular sclerosis did not exceed
10% in individuals under 40 years of age [61]. With increasing
age, however, the frequency of sclerotic glomeruli reached
almost 30%. Kappel and Olsen reported similar findings, that is,
a highly significant correlation between age and percentage of
sclerotic glomeruli [62]. The weight of total renal and cortical
mass decreases to about one-half between the ages of 40 and 80
to 90 years. During the same time span, renal hemodynamics
and functional tubular mass decrease by 40% to 50% [63].
Although it is generally held that abiotrophic involutional
sclerosis of glomeruli is secondary to vascular sclerosis,
McLachlan et al failed to find a significant correlation between
vascular changes and glomerular sclerosis in the aging kidney
[64]. An understanding of the mechanisms responsible for
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glomerular involution with aging might provide insights into
disease progression.
Aminonucleoside nephrotic syndrome and glomerular sclero-
sis. A model of chronic renal disease utilizing repeated injec-
tions of aminonucleoside, an agent that usually produces a
reversible renal lesion when given in a single course, was
described by Wilson and associates in 1958 [65]. Others subse-
quently have investigated the presumed nonimmunologic
pathogenesis of this form of renal injury [66]. Most recently,
Glasser, Velosa, and Michael reported that an apparent thresh-
old level of protein excretion was essential for the development
of focal glomerular sclerosis in this model [67]. Many groups
have proposed that in this model of focal sclerosis, irreversible
epithelial cell injury is the primary pathogenetic mechanism that
leads to eventual glomerular sclerosis as a result of increased
protein permeability, deposition of fibrin and related antigens,
and protein-aggregate accumulation in the mesangium and
subendothelium [68—72]. "Mesangial overload," the basis for
glomerular injury and sclerosis hypothesized in this model,
might prove to be one of the nonimmunologic mechanisms
responsible for progression of renal disease in humans.
Glomerular sclerosis in reflux nephropathy. Investigations
into the progression of renal insufficiency after the surgical
correction of reflux nephropathy have disclosed the occurrence
of a focal, segmental, sclerosing glomerular lesion that often is
associated with heavy proteinuria [73—771. Immunopathologic
studies suggest a possible immune mechanism of glomerular
damage [78], but progressive parenchymal damage in this
situation might represent still another example of the deleteri-
ous effects of adaptation to loss of renal mass on remaining
intact nephrons.
Summary. Let me now summarize what these data have
taught us. Our long-term observations in poststreptococcal
glomerulonephritis and other glomerular diseases suggested
that nonimmunologically mediated damage often was related to
ischemia secondary to intrarenal vascular sclerosis which, in
turn, could be attributed to hypertension. However, a new basis
for glomerular obliteration has emerged from physiologic and
morphologic studies of reduced renal mass, the aging kidney,
post-salt or steroid-induced hypertension, and various forms of
hypertension superimposed on experimental nephritis. It ap-
pears that nephron loss begets further glomerular damage
through adaptive hemodynamic changes that take place in
remaining nephrons and that expose the glomerular capillaries
to increased flows and hydraulic pressures. When systemic
hypertension occurs in conjunction with glomerulonephritis,
glomerular damage is further increased, possibly through in-
creased transmission of elevated pressures. One can hypothe-
size that elevated glomerular pressure and consequent hyperfu-
sion rather than ischemia is the mechanism by which hyperten-
sion aggravates glomerulonephritis: a failure of autoregulation
in nephrons adapted to disease. The mechanism by which
increments in glomerular capillary hydraulic pressure eventual-
ly result in sclerosis and obliteration of capillaries is not known,
but epithelial cell damage with alterations in permselectivity
and resultant mesangial overload and dysfunction might be
responsible. The adverse effects of dietary protein and the
protective role of phosphorus restriction might operate through
similar mechanisms, in which altered glomerular hemodynam-
ics play a key role.
Questions and answers
DR. JOHN T. HARRINGTON: Do you think that the fact that
hypertension superimposed on nephrotoxic serum nephritis
results in glomerular sclerosis gives us any insight into the
pathogenesis of the focal sclerosis that occurs in patients with
idiopathic nephrotic syndrome?
DR. BALDWIN: Insight into the pathogenesis of focal glomer-
ulosclerosis may be gained from the work I cited by Michael
and his associates on the model of this lesion that can be
produced by chronic administration of aminonucleoside [67,
68]. These studies and the observations on proteinuria and the
development of glomerular sclerosis in the aging rat kidney [56—
60] and in the remnant kidney [22] suggest that increased
permeability to large molecules may be responsible for glomer-
ular damage. In other words, proteinuria may not be only the
passive result of abnormal glomerular capillary permeability;
the increased passage of proteins may in itself cause further
glomerular damage, possibly through "measangial overload."
This hypothesis revives the old argument as to whether minimal
change nephrotic syndrome can evolve into focal segmental
glomeruloscierosis. Some patients seem to have minimal
change as evidenced by biopsy and by the characteristic
response to steroids, but they then become steroid resistant and
progress to renal failure. This suggests that proteinuria itself
may actually be damaging. Thus, in patients with minimal-
change nephrotic syndrome, the goal of inducing a remission
may be more important than simply raising serum albumin and
ridding the patient of edema. By correcting the defect that
allows the protein leak, one acually may be preventing the
development of glomerular sclerosis.
DR. HARRINGTON: That is interesting because the data from
both the Collaborative Study of the Adult Idiopathic Nephrotic
Syndrome [79] and our combined Boston University-Tufts
nephrotic syndrome study [80] show a very good correlation
between the degree of proteinuria and renal function. Renal
function remained normal in all patients with protein excretion
of less than 2 g/day.
DR. JORDAN J. COHEN: I gather from your thesis that you
would predict that further progression is inevitable once a
patient with chronic glomerulonephritis reaches a certain criti-
cal level of renal insufficiency. Have you had the experience of
seeing patients—as we thought we were seeing in today's first
case—with serum creatinine levels of 4 or 5 mgldl for many
years who go on to live a normal lifetime and die from other
causes?
DR. BALDWIN: Rarely, except in the elderly. A serious
problem almost certainly exists if a patient with chronic renal
disease loses function beyond a certain level, say 50%. We used
to say that when glomerulonephritis goes into the hypertensive
stage, you can count the years that patient will survive. I think
what that really implied was that when the "magic number" of
nephrons has been lost and the remaining ones have adapted to
this loss, and hypertension is then added that is "unopposed,"
sclerosis of remaining arterioles and glomeruli is inevitable. The
creatinine clearance seems to decrease arithmetically early in
the patient's course. Then in the last 3 or 4 years it declines
more rapidly. I think this change occurs because adapted
nephrons and their arterioles are highly susceptible to the
effects of hypertension. I don't wish to appear dogmatic in this
regard. The reverse also occurs: loss of nephrons itself causes
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the hypertension. We may have to invoke the old "vicious
cycle" here. Who can say which comes first? I think that the
reason we were able to show what we did was because our
model of experimental hypertension employed a renal artery
clip, which does more than just produce hypertension. Clipping
the kidney, and essentially ablating it functionally, increases the
work of the remaining kidney: not only is the kidney nephritic
and exposed to hypertension, but it also must adapt to having
lost its mate. Thus, the perfect set-up for vascular and glomeru-
lar sclerosis is established.
DR. STEVEN ZELMAN (Renal Fellow, NEMC): Since the
glomerular blood flow and glomerular pressures would be
increased even if the systemic blood pressure were normal in
patients who have a serum creatinine of 4 mgldl, should we
perhaps be lowering the blood pressure to subnormal levels so
as to further reduce the glomerular pressure, and perhaps to
protect these patients to some extent from this added adaptive
hypertension?
DR. BALDWIN: That's an interesting theoretical consider-
ation, but I don't know how much leeway you would have. If
you lower the blood pressure in a patient with reduced nephron
mass, the remaining nephrons, if not already maximally per-
fused, might undergo further vasodilation. When you reduce a
normal individual's blood pressure, the renal arterioles con-
strict. Perhaps in the diseased kidney, adaptive mechanisms
would continue to maintain flow even in the presence of
reduced blood pressure. You are suggesting that in renal
disease, we might maintain patients chronically under the stress
of hypotension so that they might override their adaptive
vasodilation. We thus would raise their creatinine and BUN
levels but would spare their glomeruli the deleterious effects of
increased pressures and hyperfusion. I'm not prepared to
conjecture on the validity of this suggestion.
DR. MICHAEL MADAIO (Renal Service, NEMC): Do you
think that the pathogenesis and subsequent course of the
epidemic form of poststreptococcal glomerulonephritis is differ-
ent than the sporadic form you are reporting? If the prognosis is
better in the epidemic form of the disease, as many investiga-
tors claim, is it due simply to a difference in the way that
patients have been studied?
DR. BALDWIN: Yes. I believe that patients with the epidemic
form of acute PSGN do have a better prognosis. Some very
good studies, such as those carried out in Trinidad, show that
patients with epidemic PSGN do much better than patients with
sporadic cases, at least over the first decade. Seven to 12 years
was the period covered in the longest follow-up from Trinidad,
which was published in 1979 [81]. Because this study included
fewer patients with renal functional impairment or even protein-
uria or hypertension, I think that epidemic nephritis (at least in
Trinidad) is milder than is sporadic nephritis, and that many
cases that would not be recognized sporadically are picked up
during epidemics; possibly both theories are true. In general, it
is acknowledged that during epidemics instances of mild nephri-
tis are detected that otherwise would be missed. However,
many of these children in Trinidad did not have mild disease.
There must be some other explanation for the better prognosis
of epidemic PSGN. For one thing, young people are primarily
affected. We know, from our own sporadic cases [82] and the
reports of others [83], that youngsters are affected less severely
and that they do better at least over the first 10 to 15 years from
onset than do adults. The fact that adults do worse may be
related to the greater vulnerability of the aging kidney to
glomerular sclerosis. To return to your question, I agree that
there is a difference. I really don't know the reason for this
difference except that more younger patients with milder dis-
ease may have been included in the studies of epidemics.
DR. JAMES STROM (Renal Division, St. Elizabeth's Hospital,
Boston, Mass.): Following your hypothesis, if you look at
patients with progressive renal failure from interstitial disease
but without hypertension, do you find progressive glomerular
sclerosis in that instance as well?
DR. BALDWIN: Yes. But I still think that the observation that
patients with tubulointerstitial diseases often progress more
slowly than do those with primary glomerular disease is related
to the fact that hypertension is less common or milder in
interstitial nephritides, including pyelonephritis. We know that
essential hypertension can last for 50 years and not lead to renal
failure, but the presence or absence of hypertension makes a
great difference in the rate of progression of intrinsic renal
diseases, whether glomerular or tubulointerstitial.
DR. COHEN: Kincaid-Smith and others have pointed out that
patients with interstitial nephritis due to analgesic-abuse neph-
ropathy, for example, may develop a very prominent glomeru-
losclerosis or focal sclerosis after many years [84. Such
occurrences may be relevant to your hypothesis.
DR. BALDWIN: That is a very pertinent comment. It is of
particular interest, I believe, that these patients progress to
renal failure even after they discontinue taking analgesics; this
might be another example of sclerosis developing in remnant
nephrons because of adaptation. Hypertension does occur, of
course, in many of these patients and probably is responsible
for additional vascular and glomerular damage to adapted
nephrons.
DR. DAVID CLIVE (Renal Unit, Beth Israel Hospital, Boston,
Mass.): Can you apply this thesis to the natural history of
diabetic glomerular disease, in which progression of renal
failure occurs relentlessly following the appearance of protein-
uria? Do you think there is any correlation? The development of
heavy proteinuria, while obviously a sign of glomerular capil-
lary wall disease, also may be responsible for accelerating
glomerular mesangial sclerosis in diabetes mellitus.
DR. BALDWIN: Absolutely. The development of heavy pro-
teinuria obviously is evidence of glomerular capillary wall
disease. This same alteration in permselectivity of the capillary,
however, may participate in the mechanism responsible for
sclerosis in diabetes mellitus as well as other glomerular dis-
ease.
DR. NIcOLAOs E. MADIAS (Renal Service, NEMC): I have
two questions. First, have you had the opportunity to observe
the clinical course of patients with single kidneys who happened
to get a form of glomerular disease that was identified? Second,
have you followed patients with chronic nephritis who subse-
quently developed renovascular hypertension? Do such pa-
tients have an increase in proteinuria, a finding that would be in
accord with your experimental observations?
DR. BALDWIN: I don't know of any patients with single
kidneys who had morphologically documented acute glomeru-
lonephritis. We would not hazard a renal biopsy in such
patients. We have under observation patients with other forms
of glomerular disease in whom it was deemed important to get a
Nonimmunologic mechanisms of glomerulonephritis 119
biopsy, and an open one was obtained because of unilateral
renal agenesis. There are too few patients of this kind, however,
to say whether they fare worse than do nephritics with two
kidneys. I don't know of any of our patients with nephritis who
have developed superimposed renovascular hypertension. A
few individuals have been described who have renovascular
hypertension and the nephrotic syndrome. I have often won-
dered if they did not perhaps have underlying glomerulonephri-
tis.
Reprint requests to Dr. David S. Baldwin, Hypertension and Renal
Disease Section, New York University School of Medicine, 550 First
Avenue, New York, New York 10016, USA
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